Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin compared to Empagliflozin
{{output}}
While selective SGLT2 inhibitors improve heart failure (HF) outcomes, they do not consistently reduce atherothrombotic events (myocardial infarctions and strokes). Clinical trials with sotagliflozin, the first dual SGLT1/2 inhibitor, have shown significant red... ...
